Drug Trial Radar · NCT07869134
Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Oct 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Forward TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate if the study medicine FT2109 can treat symptoms of active Psoriatic Arthritis (PsA). This study assesses the safety and efficacy of FT2109 in adult participants with active PsA who may or may not have been treated previously with advanced therapy and who may be on stable background therapy. In this study, researchers will look at different doses of FT2109 compared to placebo (a treatment with no active study drug in it). Researchers will try to learn if at least one of the study doses of FT2109 works better than placebo to treat PsA symptoms.
Conditions
- Psoriatic Arthritis (PsA)
Interventions
FT2109 Dosing Regimen 1Drug
Administered daily for 12 weeks
FT2109 Dosing Regimen 2Drug
Administered daily for 12 weeks
Matching PlaceboDrug
Administered daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who achieved an American College of Rheumatology (ACR) 20 response at Week 12Time frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.